Login to Your Account

Simeprevir Heads to Gate with Upbeat Phase III Data

By Marie Powers
Staff Writer

Friday, October 18, 2013
Medivir AB reported preliminary data from two Phase III studies of simeprevir conducted by partner Janssen R&D Ireland, suggesting the once-daily NS3/4A protease inhibitor could additionally benefit individuals with genotype 1 hepatitis C virus (HCV) co-infected with HIV-1 and patients with genotype 4 chronic HCV who have compensated liver disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription